Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for OGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 3.671M
March 31, 2026 6.182M
December 31, 2025 8.281M
September 30, 2025 9.831M
June 30, 2025 -2.128M
March 31, 2025 0.1377M
December 31, 2024 -0.2119M
September 30, 2024 3.078M
June 30, 2024 1.326M
March 31, 2024 2.625M
December 31, 2023 3.168M
September 30, 2023 6.497M
June 30, 2023 7.258M
March 31, 2023 10.24M
December 31, 2022 13.01M
September 30, 2022 15.27M
June 30, 2022 16.79M
March 31, 2022 21.99M
December 31, 2021 26.49M
September 30, 2021 28.55M
June 30, 2021 32.73M
March 31, 2021 36.05M
December 31, 2020 16.84M
September 30, 2020 9.640M
June 30, 2020 8.788M
Date Value
March 31, 2020 12.91M
December 31, 2019 17.23M
September 30, 2019 20.82M
June 30, 2019 24.42M
March 31, 2019 29.12M
December 31, 2018 20.88M
September 30, 2018 13.98M
June 30, 2018 3.651M
March 31, 2018 4.315M
December 31, 2017 6.316M
September 30, 2017 1.013M
June 30, 2017 0.5055M
March 31, 2017 1.186M
December 31, 2016 2.996M
September 30, 2016 5.502M
June 30, 2016 7.239M
March 31, 2016 2.874M
December 31, 2015 4.731M
September 30, 2015 1.503M
June 30, 2015 3.094M
March 31, 2015 9.156M
December 31, 2014 10.34M
September 30, 2014 11.56M
June 30, 2014 12.56M
March 31, 2014 14.20M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics